Kevin Prehn Sells Shares of UTI

Kevin Prehn, the Concorde Division President at UTI, sold 4,545 shares of the company on June 22, 2026. The shares were sold at an average price of $40.00, bringing the total transaction value to $181,800. This transaction was not part of a prearranged trading plan.

Other Institutional Activity in UTI

Coliseum Capital Management, LLC held steady with its 3,971,440 shares worth about $143.4 million. BlackRock, Inc. trimmed its holdings by 7,414 shares and now holds 3,623,372 shares valued at approximately $130.8 million, reflecting a 0.2% decrease. Vanguard Capital Management LLC opened a new position with 2,172,384 shares, valued at about $78.4 million. Congress Asset Management Co increased its stake by 458,805 shares, now holding 2,152,978 shares worth around $77.7 million, marking a 27.1% increase. Wasatch Advisors LP added 223,893 shares, bringing its total to 1,978,776 shares valued at $71.4 million, a 12.8% increase.

Universal Technical Institute, Inc. Stock Up 84.7%

Shares of UTI traded near $39.75 on Thursday. The company has a market capitalization of $1.48 billion. UTI's stock has seen a 52-week low of $34.50 and a high of $41.75. The stock's 50-day moving average is $38.00, while the 200-day moving average is $37.50.

Insider Buying and Selling at Universal Technical Institute, Inc.

Several insiders have been active in trading UTI shares recently. On June 22, 2026, Kevin Prehn sold 4,545 shares at $40.00 each. Earlier in June, Coliseum Capital Management, LLC sold 3,000,000 shares at $41.40, and Christine Kline, Senior Vice President and CAO, sold 3,500 shares at $44.42 on June 5. Tracy Kay Lorenz, SVP and UTI Division President, sold 22,073 shares at $40.06 on May 27.

Analysts Set New Price Targets

On May 7, 2026, Barrington Research maintained its 'buy' rating on UTI with a price target of $42. Rosenblatt also maintained a 'buy' rating with a target of $45. The consensus among analysts is a 'buy' rating, with an average price target of around $38.50 based on multiple opinions.

About UTI

UTI, headquartered in [Location], operates in the [Industry] sector. The company offers [products/services], catering to [target market]. UTI is led by CEO [Name] and employs approximately [number] people.

Bottom Line

Kevin Prehn's recent sale of UTI shares is part of ongoing insider activity. Institutional investors have been adjusting their positions, reflecting varied strategies in response to market conditions. Analysts continue to show confidence in UTI with 'buy' ratings and price targets above the current trading levels. As always, these insider and institutional activities, along with analyst opinions, provide valuable insights into market sentiment but are backward-looking and should be one of many factors considered by investors.